Skip to content

Intrapleural Urokinase for Retained Hemothorax

Intrapleural Thrombolytic Treatment With Urokinase for Retained Hemothorax: A Prospective Double-blinded Randomized Multicenter Study

Status
UNKNOWN
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01134237
Acronym
NTUH
Enrollment
32
Registered
2010-05-31
Start date
2010-05-31
Completion date
2013-08-31
Last updated
2010-05-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Retained Hemothorax

Keywords

non-surgical rate

Brief summary

Intrapleural thrombolytic treatment with urokinase for retained hemothorax is effective and safe. However, previous study was limited in prospective observation study without control group.

Detailed description

We will recruit 32 patients in this study. The patients with retained hemothorax will be randomly divided into the urokinase group and the placebo group. In the urokinase group, urokinase 100,000 IU in 100 mL NaCl will be injected into the intrapleural space. We will record the daily drainage amount and evaluate the therapeutic effect by the chest X-ray. The therapeutic effect, safety, hospital stay, and medical cost between the two groups will be compared. This study will be done in four medical centers in northern Taiwan.

Interventions

intrapleural urokinase injection

DRUGplacebo

Normal saline as a placebo for control arm

Sponsors

National Taiwan University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Retained hemothorax: it is defined as chest X-ray revealing obvious blood clot in pleural cavity after tube thoracostomy drainage for 3 days. The chest tubes are in good location and have no obstruction. The physician thinks the blood clot is difficult to drain. 2. Age: full 18 year-old

Exclusion criteria

1. Pregnancy 2. Active bleeding 3. Coagulopathy, e.g. congenital or acquired coagulation abnormality, platelet count less than 100,000 /μL, international normalized ratio (INR) more than 1.5, or partial thromboplastin time, PTT, more than 50 seconds after treatment. 4. Cerebrovascular accident within 30 days 5. History of intracranial tumor or vascular abnormality 6. Have received thoracic surgery 7. Have received pleurodesis 8. Wish to receive thoracoscopic surgery for hematoma evacuation directly 9. Allergy to urokinase 10. Sepsis 11. Shock 12. People who are less than 18 years of age, prisoners, aborigines.

Design outcomes

Primary

MeasureTime frameDescription
non-surgical rateabout 5 daysComplete response and partial response

Countries

Taiwan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026